Neoadjuvant chemotherapy (NAC) with dose-dense gemcitabine/cisplatin (DDGC) in localized muscle-invasive bladder cancer (MIBC).

George Tsironis,Roubini Zakopoulou,Konstantinos Koutsoukos,Kimon Tzanis,J. Varkarakis,Athanasios Papatsoris,K. Stravodimos,Efthymios Kostouros,C. Fragkoulis,Theodosia Choreftaki,Dimitrios K. Filippiadis,Sofia Fontara,Athanasios Dellis,Sparti Ntai,Anna Zygogianni,Konstantinos Ntoumas,Constantinos Constantinides,Penelope Korkolopoulou,Meletios A. Dimopoulos,Aristotelis Bamias

Neoadjuvant chemotherapy (NAC) with dose-dense gemcitabine/cisplatin (DDGC) in localized muscle-invasive bladder cancer (MIBC).

2018

e16527Background: NAC prior to radical cystectomy (RC) with MVAC or GC represents a standard for non-metastatic MIBC. DDGC has shown similar efficacy and favorable toxicity to DDMVAC in metastatic ...

Keywords:

Pathology
Oncology
Bladder cancer
Gemcitabine/cisplatin
Chemotherapy
Medicine
Internal medicine
muscle invasive
Toxicity
Cystectomy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations